Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Incyte corporation source : Www.biospace.com save search
Incyte to Report First Quarter Financial Results - April 11, 2024
Published: 2024-04-11 (Crawled : 21:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.62%
H: 1.17%
C: -0.76%
first report financial results
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: -0.58%
license collaboration asia agreement
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.07%
H: 0.09%
C: -0.7%
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -0.66%
H: 4.19%
C: 3.13%
MOR | $17.96 -0.5% -0.5% 180K
|
Health Technology
|
| O: 0.22%
H: 0.22%
C: -0.93%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.03%
H: 1.47%
C: -0.72%
year update financial results
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
Published: 2024-03-04 (Crawled : 14:30) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.34%
H: 0.89%
C: 0.79%
meeting growing
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
Published: 2024-02-27 (Crawled : 23:00) - biospace.com/
SNDX | $20.82 1.61% 1.59% 850K
|
Health Technology
|
| O: 0.88%
H: 1.12%
C: -0.73%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.2%
H: 1.37%
C: 0.58%
drug disease review food treatment grants
Incyte to Present at Upcoming March 2024 Investor Conference
Published: 2024-02-15 (Crawled : 14:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.35%
H: 3.06%
C: 1.51%
conference
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
Published: 2024-02-13 (Crawled : 19:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.14%
H: 0.35%
C: 0.07%
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -3.56%
H: 2.91%
C: -3.34%
MOR | $17.96 -0.5% -0.5% 180K
|
Health Technology
|
| O: -0.4%
H: 0.23%
C: -0.46%
MGNX | $15.62 -2.8% -2.88% 1M
|
Health Technology
|
| O: -5.25%
H: 2.94%
C: 2.18%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 3.8%
H: 1.1%
C: -1.17%
financial
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
Published: 2024-02-05 (Crawled : 23:00) - biospace.com/
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -1.55%
H: 2.76%
C: 1.84%
MOR | $17.96 -0.5% -0.5% 180K
|
Health Technology
|
| O: 0.99%
H: 59.84%
C: 54.47%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.6%
H: 0.81%
C: 0.1%
monjuvi global commercialization
Agilent Announces Collaboration with Incyte to Develop Advanced Companion Diagnostics in Hematology and Oncology
Published: 2024-01-30 (Crawled : 14:00) - biospace.com/
A | $132.73 0.22% 0.0% 1.3M
|
Health Technology
|
| O: 0.0%
H: 1.27%
C: 1.09%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: -2.02%
collaboration companion diagnostics advanced
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
Published: 2024-01-23 (Crawled : 14:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.37%
H: 0.75%
C: 0.23%
report financial results
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-08 (Crawled : 16:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.55%
H: 1.45%
C: 1.42%
conference business growth
Incyte to Present at Upcoming Investor Conferences - December 12, 2023
Published: 2023-12-12 (Crawled : 15:30) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.56%
H: 8.87%
C: 7.85%
Innovent Presents Clinical Data Update of IBI351 (KRAS G12C Inhibitor) Monotherapy in Lung Cancer and Colorectal Cancer at ESMO Asia Congress 2023
Published: 2023-12-01 (Crawled : 06:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.39%
H: 0.0%
C: -0.05%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.15%
H: 0.35%
C: -0.74%
ibi351 lung congress update cancer asia
AnHeart Therapeutics and Innovent Announce China’s NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor)
Published: 2023-11-22 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.74%
H: 0.71%
C: 0.71%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.56%
H: 1.06%
C: -0.24%
drug application therapeutics
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
Published: 2023-11-02 (Crawled : 18:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.09%
H: 1.03%
C: 0.91%
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: 1.32%
H: 0.45%
C: -1.19%
MOR | $17.96 -0.5% -0.5% 180K
|
Health Technology
|
| O: 2.22%
H: 0.6%
C: -9.4%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.28%
H: 1.0%
C: -0.46%
presentation meeting
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2023-10-31 (Crawled : 00:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 1.05%
H: 0.74%
C: 0.74%
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -0.41%
H: 2.1%
C: 1.11%
MOR | $17.96 -0.5% -0.5% 180K
|
Health Technology
|
| O: 4.23%
H: 0.12%
C: -1.97%
MGNX | $15.62 -2.8% -2.88% 1M
|
Health Technology
|
| O: 0.0%
H: 2.13%
C: 1.16%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.39%
H: 4.09%
C: 3.8%
financial results
Incyte to Present at Upcoming Investor Conferences - October 18, 2023
Published: 2023-10-18 (Crawled : 13:30) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.23%
H: 1.1%
C: -0.42%
Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023
Published: 2023-10-16 (Crawled : 19:00) - biospace.com/
MGNX | $15.62 -2.8% -2.88% 1M
|
Health Technology
|
| O: 0.59%
H: 3.33%
C: 1.37%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.62%
H: 0.16%
C: -0.59%
congress
Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
Published: 2023-10-13 (Crawled : 23:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.27%
H: 2.14%
C: 2.11%
symposium program
Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
Published: 2023-10-13 (Crawled : 23:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.27%
H: 2.14%
C: 2.11%
opzelura children dermatitis
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.